Dual Endothelin Receptor Blockade Acutely Improves Insulin Sensitivity in Obese Patients With Insulin Resistance and Coronary Artery Disease
Open Access
- 1 March 2007
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (3), 591-596
- https://doi.org/10.2337/dc06-1978
Abstract
OBJECTIVE—Endothelin (ET)-1 is a vasoconstrictor and proinflammatory peptide that may inhibit glucose uptake. The objective of the study was to investigate if ET (selective ETA and dual ETA+ETB) receptor blockade improves insulin sensitivity in patients with insulin resistance and coronary artery disease.Keywords
This publication has 27 references indexed in Scilit:
- Endothelin‐1 impairs glucose transporter trafficking via a membrane‐based mechanismJournal of Cellular Biochemistry, 2005
- Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibitionJournal of Internal Medicine, 2005
- Endothelium-Restricted Overexpression of Human Endothelin-1 Causes Vascular Remodeling and Endothelial DysfunctionCirculation, 2004
- Endothelin-A Receptor Antagonism Reduces Blood Pressure and Increases Renal Blood Flow in Hypertensive Patients With Chronic Renal FailureCirculation, 2004
- Combined Endothelin Receptor Blockade Evokes Enhanced Vasodilatation in Patients With AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Endothelial dysfunction in diabetesBritish Journal of Pharmacology, 2000
- Plasma endothelin-1 levels in obese hypertensive and normotensive menDiabetes, 1995
- Circulating Endothelin-1 Levels Increase During Euglycemic, Hyperinsulinemic Clamp in Lean NIDDM MenDiabetes Care, 1995
- Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptorNature, 1990
- Cloning and expression of a cDNA encoding an endothelin receptorNature, 1990